Hilltop Holdings Inc. Sells 1,823 Shares of Stryker Corporation $SYK

Hilltop Holdings Inc. reduced its holdings in shares of Stryker Corporation (NYSE:SYK) by 38.8% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,878 shares of the medical technology company’s stock after selling 1,823 shares during the period. Hilltop Holdings Inc.’s holdings in Stryker were worth $946,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the business. Varma Mutual Pension Insurance Co raised its stake in shares of Stryker by 10.5% in the fourth quarter. Varma Mutual Pension Insurance Co now owns 53,610 shares of the medical technology company’s stock valued at $18,842,000 after acquiring an additional 5,100 shares during the last quarter. Wealthcare Advisory Partners LLC grew its position in Stryker by 265.2% during the 4th quarter. Wealthcare Advisory Partners LLC now owns 9,328 shares of the medical technology company’s stock worth $3,278,000 after acquiring an additional 6,774 shares during the last quarter. QRG Capital Management Inc. increased its holdings in Stryker by 7.4% during the 4th quarter. QRG Capital Management Inc. now owns 60,548 shares of the medical technology company’s stock valued at $21,281,000 after purchasing an additional 4,186 shares in the last quarter. Chesley Taft & Associates LLC increased its holdings in Stryker by 2.3% during the 4th quarter. Chesley Taft & Associates LLC now owns 141,083 shares of the medical technology company’s stock valued at $49,586,000 after purchasing an additional 3,230 shares in the last quarter. Finally, Fulton Breakefield Broenniman LLC raised its position in Stryker by 41.3% in the 4th quarter. Fulton Breakefield Broenniman LLC now owns 50,123 shares of the medical technology company’s stock valued at $17,617,000 after purchasing an additional 14,641 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Stock Performance

Stryker stock opened at $330.69 on Monday. The company has a market cap of $126.78 billion, a PE ratio of 38.27, a PEG ratio of 2.12 and a beta of 0.77. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $404.14. The company’s 50-day moving average is $314.69 and its two-hundred day moving average is $335.57.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.38). The business had revenue of $6.02 billion for the quarter, compared to analyst estimates of $6.34 billion. Stryker had a return on equity of 23.42% and a net margin of 13.20%.The firm’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Equities analysts anticipate that Stryker Corporation will post 14.99 earnings per share for the current year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be paid a $0.88 dividend. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. Stryker’s dividend payout ratio is 40.74%.

Wall Street Analyst Weigh In

SYK has been the topic of several research analyst reports. Weiss Ratings cut Stryker from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 4th. BMO Capital Markets assumed coverage on shares of Stryker in a research report on Wednesday, July 8th. They issued an “outperform” rating and a $369.00 price objective for the company. Argus set a $370.00 target price on shares of Stryker in a research report on Thursday, July 9th. The Goldman Sachs Group reissued a “neutral” rating and issued a $361.00 price target on shares of Stryker in a report on Friday, May 1st. Finally, BTIG Research set a $371.00 price objective on shares of Stryker in a research report on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $392.52.

Insider Activity

In other news, VP Robert S. Fletcher sold 4,544 shares of the firm’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the transaction, the vice president directly owned 10,582 shares in the company, valued at $3,247,298.34. This trade represents a 30.04% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP M Kathryn Fink sold 5,220 shares of Stryker stock in a transaction on Monday, May 11th. The stock was sold at an average price of $283.85, for a total value of $1,481,697.00. Following the sale, the vice president directly owned 13,137 shares of the company’s stock, valued at approximately $3,728,937.45. This trade represents a 28.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 323,264 shares of company stock valued at $100,659,489 in the last 90 days. 4.60% of the stock is owned by company insiders.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.